The Food and Drug Administration may delay its decision on Zogenix Inc.'s (Nasdaq: ZGNX) pure hydrocone pain treatment Zohydro but the pharmaceutical remained confident of approval. Shares of the pharmaceutical leaped 49 cents to close at $1.70.